AstraZeneca: Diabetes Mellitus, Type 2 trials

The registry lists 345 Diabetes Mellitus, Type 2 studies with AstraZeneca as lead sponsor. 13 are open to participants now and 149 have results posted.

Phase 1 89Phase 2 47Phase 3 122Phase 4 28No phase 65(a study in two phases counts in both)

Studies

Page 3 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in TaiwanCompletedNCT03084965
• Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory DataCompletedNCT03078049
• Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian PatientsCompletedNCT03071016
• XIGDUO Extended Release (XR) Post Marketing SurveillanceCompletedNCT03038789
• Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 InhibitorsCompletedNCT02993614
• Clinical Outcomes of Exenatide Versus Basal InsulinCompletedNCT02987348
• Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal InsulinsCompletedNCT02974244
• Study With DapagliflozinCompletedNCT02971618
• Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)CompletedNCT02935712Phase 1
• Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal ImpairmentCompletedNCT02917057
• Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable TherapyCompletedNCT02843399
• Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes MellitusCompletedNCT02805361
• Dapagliflozin Patient Satisfaction SurveyCompletedNCT02805283
• A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes MellitusTerminatedNCT02749435
• Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActiceWithdrawnNCT02719132Phase 4
• Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus PatientsCompletedNCT02588859
• A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 DiabetesCompletedNCT02524782Phase 1
• Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin.CompletedNCT02355145
• DISCOVERing Treatment Reality of Type 2 Diabetes in Real World SettingsCompletedNCT02322762
• Forxiga (Dapagliflozin) Regulatory Postmarketing SurveillanceCompletedNCT02252224
• DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in JapanCompletedNCT02226822
• An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes PatientsCompletedNCT02208921
• Forxiga Tablets Specific Clinical Experience Investigation for Long-term UseCompletedNCT02200666
• Forxiga Tablets Specific Clinical Experience Investigation for ElderlyCompletedNCT02200627
• Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In KoreaCompletedNCT02090673
• Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)CompletedNCT02060201Phase 1
• forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)TerminatedNCT01944618
• Specific Clinical Experience Investigation for Long-term Use of Bydureon.CompletedNCT01940770
• An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes MellitusCompletedNCT01876849Phase 3
• Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)CompletedNCT01817569
• Extension Study for 2993-112CompletedNCT01789957Phase 3
• A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-AdministrationCompletedNCT01755494Phase 1
• Korean Post-marketing Surveillance for Kombiglyze XR®CompletedNCT01754142
• Better Diabetes Control, Quality - Educate to Achieve Compliance.CompletedNCT01728714
• OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEACompletedNCT01694758
• Korean Post-marketing Surveillance for Onglyza®CompletedNCT01575483
• Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in FranceCompletedNCT01552005
• To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered SeparatelyCompletedNCT01535677Phase 1
• A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DMCompletedNCT01523405
• Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic TreatmentsCompletedNCT01377935
• BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed StatesWithdrawnNCT01305551Phase 1
• Management of Dyslipidemia in Adult Type 2 Diabetes Patients in IndiaCompletedNCT01292018
• Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their UsageCompletedNCT01275794
• Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise AloneSuspendedNCT01257412Phase 3
• Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.TerminatedNCT01244646
• A Study Conducted Over 3 Periods to Look at the Drug in the BodyCompletedNCT01225939Phase 1
• Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual UseTerminatedNCT01223456
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM PatientsCompletedNCT01221545Phase 1
• A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT01221519Phase 1
• Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687CompletedNCT01217905Phase 1
• Risk Factors for Low Lymphocyte Count in Patients With Type 2 DiabetesCompletedNCT01192659
• Hypoglycemia: Physician and Patient PerspectivesCompletedNCT01176656
• To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 DiabetesCompletedNCT01176097Phase 1
• Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT01165268Phase 1
• Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy VolunteersCompletedNCT01156246Phase 1
• Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical StudyCompletedNCT01140542Phase 2
• Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy SubjectsCompletedNCT01135446Phase 1
• A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary CareCompletedNCT01121315
• Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus PatientsCompletedNCT01103622Phase 1
• Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT01103609Phase 1
• Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With SimvastatinCompletedNCT01096940Phase 1
• Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes MellitusCompletedNCT01095991Phase 1
• Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic TreatmentsCompletedNCT01086319
• Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic TreatmentCompletedNCT01086306
• Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic TreatmentsCompletedNCT01086293
• Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic TreatmentsCompletedNCT01086280
• To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656CompletedNCT01083212Phase 1
• Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes MellitusCompletedNCT01082120Phase 1
• Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy SubjectsTerminatedNCT01068756Phase 1
• Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT01055652Phase 1
• Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted StateCompletedNCT01002807Phase 1
• Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and SulfonylureaCompletedNCT00995787Phase 1
• Evaluation of Diabetes Care at Austrian GPsTerminatedNCT00979394
• Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)CompletedNCT00960791Phase 1
• Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy SubjectsCompletedNCT00935467Phase 1
• Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy SubjectsCompletedNCT00930865Phase 1
• To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT00916604Phase 1
• Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy SubjectsCompletedNCT00908271Phase 1
• Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy SubjectsCompletedNCT00904176Phase 1
• Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic PatientsTerminatedNCT00886366Phase 1
• Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy SubjectsCompletedNCT00842556Phase 1
• Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral DosesCompletedNCT00841048Phase 1
• Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy SubjectsCompletedNCT00839683Phase 1
• To Evaluate 24-hr Glucose After OD vs BD AZD1656CompletedNCT00819884Phase 1
• To Evaluate the Response to Glucagon During HypoglycemiaCompletedNCT00817271Phase 1
• Survey on the Treatment of Hypertension in Patients With Type 2 DiabetesCompletedNCT00803660
• To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 SuspensionCompletedNCT00790153Phase 1
• To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of MetforminCompletedNCT00774553Phase 1
• Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of SaxagliptinCompletedNCT00770302Phase 1
• To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of InsulinCompletedNCT00768105Phase 1
• A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 DiabetesCompletedNCT00747175Phase 1
• A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic PatientsCompletedNCT00690287Phase 1
• Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino PatientsCompletedNCT00622323
• A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 DiabetesCompletedNCT00612794Phase 1
• Exenatide Pregnancy Registry - Type 2 Diabetes in PregnancyTerminatedNCT00579150
• Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy SubjectsCompletedNCT00562250Phase 1
• Renal Impairment in Type 2 Diabetic SubjectsCompletedNCT00554450Phase 1
• Phase I Multiple-Ascending Dose (Japan)CompletedNCT00538174Phase 1
• A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT00517283Phase 1
• A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusCompletedNCT00477581Phase 4